Development of 124I immuno-pet targeting tumor vascular TEM1/endosialin

Journal of Nuclear Medicine

Volumn 55, Issue 3, 2014, Pages 500-507

  Chacko, Ann Marie ^a   Li, Chunsheng ^a   Nayak, Madhura ^a   Mikitsh, John L ^a   Hu, Jia ^a   Hou, Catherine ^a   Grasso, Luigi ^a   Nicolaides, Nicholas C ^b   Muzykantov, Vladimir R ^a   Divgi, Chaitanya R ^a   Coukos, George ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Morphotek Inc   (United States)

Author keywords

Endosialin; Immuno PET; Monoclonal antibodies; MORAb 004; TEM1

Indexed keywords

ENDOSIALIN; EPITOPE; MORAB 004; MORAB 004 I 124; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; TUMOR ENDOTHELIAL MARKER 1, MOUSE; TUMOR PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; ID8 CELL LINE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; MS1 CELL LINE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TEM1 CELL LINE; TUMOR VASCULARIZATION; VASCULAR TUMOR; ANIMAL; BLOOD VESSEL; CELL LINE; IMMUNO-PET; IMMUNOLOGY; ISOTOPE LABELING; METABOLISM; METHODOLOGY; MONOCLONAL ANTIBODIES; MORAB-004; NEOPLASM; TEM1; VASCULARIZATION;

ENDOSIALIN; IMMUNO-PET; MONOCLONAL ANTIBODIES; MORAB-004; TEM1;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BLOOD VESSELS; CELL LINE; FEMALE; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MICE; NEOPLASM PROTEINS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84899473099     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.121905     Document Type: Article

References (38)

1. St. Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science. 2000;289:1197-1202.
2. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St. Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 2001;61:6649-6655.
3. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, et al. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol. 2007;25:852-861.
4. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA. 1992;89:10832-10836.
5. Christian S, Ahorn H, Koehler A, et al. Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem. 2001;276:7408-7414.
6. Rouleau C, Curiel M, Weber W, et al. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res. 2008;14:7223-7236.
7. Simonavicius N, Robertson D, Bax DA, Jones C, Huijbers IJ, Isacke CM. Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol. 2008;21:308-315.
8. Christian S, Winkler R, Helfrich I, et al. Endosialin (Tem1) is a marker of tumorassociated myofibroblasts and tumor vessel-associated mural cells. Am J Pathol. 2008;172:486-494.
9. Bagley RG. Endosialin: from vascular target to biomarker for human sarcomas. Biomark Med. 2009;3:589-604.
10. Davies G, Cunnick GH, Mansel RE, Mason MD, Jiang WG. Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin Exp Metastasis. 2004;21:31-37.
11. Teicher BA. Newer vascular targets: endosialin. Int J Oncol. 2007;30:305-312.
12. Valdez Y, Maia M, Conway EM. CD248: reviewing its role in health and disease. Curr Drug Targets. 2012;13:432-439.
13. Carson-Walter EB, Winans BN, Whiteman MC, et al. Characterization of TEM1/ endosialin in human and murine brain tumors. BMC Cancer. 2009;9:417.
14. Rmali KA, Puntis MC, Jiang WG. Prognostic values of tumor endothelial markers in patients with colorectal cancer. World J Gastroenterol. 2005;11:1283-1286.
15. Dolznig H, Schweifer N, Puri C, et al. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun. 2005;5:10.
16. Opavsky R, Haviernik P, Jurkovicova D, et al. Molecular characterization of the mouse Tem1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo. J Biol Chem. 2001;276:38795-38807.
17. Zhao A, Nunez-Cruz S, Li C, Coukos G, Siegel DL, Scholler N. Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/ TEM1, using a paired yeast-display/secretory scFv library platform. J Immunol Methods. 2011;363:221-232.
18. Li C, Swails JL, Hasegawa K, et al. In vivo modeling and detection of the ovarian cancer vascular marker TEM1. Paper presented at: American Association for Cancer Research (AACR) - Third International Conference on Molecular Diagnostics in Cancer Therapeutic Development; September 22-25, 2008; Philadelphia, PA, United States.
19. Marty C, Langer-Machova Z, Sigrist S, Schott H, Schwendener RA, Ballmer- Hofer K. Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer Lett. 2006;235:298-308.
20. Tomkowicz B, Rybinski K, Foley B, et al. Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proc Natl Acad Sci USA. 2007;104:17965-17970.
21. Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE). ClinicalTrials.gov. March 5, 2013. http://clinicaltrials.gov/show/ NCT01574716. Accessed January 16, 2014.
22. Becker R, Lenter MC, Vollkommer T, et al. Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K. FASEB J. 2008;22:3059-3067.
23. Brady J, Neal J, Sadakar N, Gasque P. Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. J Neuropathol Exp Neurol. 2004;63:1274-1283.
24. MacFadyen JR, Haworth O, Roberston D, et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett. 2005;579:2569-2575.
25. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304-310.
26. Kenanova V, Olafsen T, Crow DM, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 2005;65:622-631.
27. Sundaresan G, Yazaki PJ, Shively JE, et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med. 2003;44:1962-1969.
28. Williams SR, Son DS, Terranova PF. Protein kinase C delta is activated in mouse ovarian surface epithelial cancer cells by 2,3,7,8-tetrachlorodibenzo-p- dioxin (TCDD). Toxicology. 2004;195:1-17.
29. Bailey G. The Iodogen method for radiolabeling protein. In: Walker JM, ed. The Protein Protocols Handbook. Totowa, NJ: Humana Press, Inc.; 1996:673-674.
30. Chacko AM, Nayak M, Greineder CF, Delisser HM, Muzykantov VR. Collaborative enhancement of antibody binding to distinct PECAM-1 epitopes modulates endothelial targeting. PLoS ONE. 2012;7:e34958.
31. Surti S, Karp JS, Perkins AE, et al. Imaging performance of A-PET: a small animal PET camera. IEEE Trans Med Imaging. 2005;24:844-852.
32. Bagley RG, Honma N, Weber W, et al. Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization. Microvasc Res. 2008;76: 180-188.
33. Bagley RG, Rouleau C, St Martin T, et al. Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248. Mol Cancer Ther. 2008;7:2536-2546.
34. Pryma DA, O'Donoghue JA, Humm JL, et al. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250. J Nucl Med. 2011;52:535-540.
35. O'Donoghue JA, Smith-Jones PM, Humm JL, et al. 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med. 2011;52:1878-1885.
36. Santoro L, Boutaleb S, Garambois V, et al. Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med. 2009;50:2033-2041.
37. Wesseling P, Schlingemann RO, Rietveld FJ, Link M, Burger PC, Ruiter DJ. Early and extensive contribution of pericytes/vascular smooth muscle cells to microvascular proliferation in glioblastoma multiforme: an immuno-light and immunoelectron microscopic study. J Neuropathol Exp Neurol. 1995;54:304-310.
38. Krauthauser C, Grasso L, Nicolaides NC, Lin JM. Neutralizing Endosialin antibody, MORAb-004, enhances efficacy of TAXOTERE in a metastatic melanoma model. Cancer Res. 2012;72(suppl 1):4410.